Last reviewed · How we verify
Phosphate Binder Agents
At a glance
| Generic name | Phosphate Binder Agents |
|---|---|
| Also known as | sevelamer carbonate, ferric citrate, calcium carbonate, calcium acetate, sucroferric oxyhydroxide |
| Sponsor | Ardelyx |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Whole-body Vibration Training in Patients With Renal Dialysis (NA)
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phosphate Binder Agents CI brief — competitive landscape report
- Phosphate Binder Agents updates RSS · CI watch RSS
- Ardelyx portfolio CI